Alpha virus-based cytomegalovirus vaccines
US7419674B2 · kind B2 · utility
32Cited by
55References
50Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 8, 2004 |
| Grant date | Sep 2, 2008 |
| Priority date | — |
| Expiry date | Jul 28, 2024 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2840/203
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides methods and compositions comprising a population of alphavirus replicon particles comprising alphavirus replicon RNAs, wherein a first replicon RNA comprises nucleic acid encoding cytomegalovirus pp65 and IE1 protein or immunogenic fragments thereof, and a second replicon RNA comprises nucleic acid encoding cytomegalovirus gB protein or an immunogenic fragment thereof, and wherein each of the two replicon RNAs is contained within a separate alphavirus replicon particle.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.